PURPOSE: Surgery and systemic chemotherapy offer modest benefit to @entity1 with recurrent @entity463 multiforme. These @entity5 are associated with rapid growth and progressive @entity16 . Radiosurgery offers a rational alternative treatment, delivering intensive local therapy. A pilot protocol to treat recurrent @entity463 was developed using fractionated stereotactic radiosurgery with concurrent intravenous (i.v.) Taxol as a radiation sensitizer. METHODS AND MATERIALS: The treatment outcome was analyzed in 14 @entity1 with recurrent @entity463 treated with fractionated stereotactic radiosurgery and concurrent Taxol. Median @entity5 volume was 15.7 cc and @entity1 received a mean radiation dose of 6.2 Gy at 90% isodose line, 4 times weekly. The median dose of @entity1311 was 120 mg/m2. RESULTS: The median survival was 14.2 months, 1-year survival was 50%. CONCLUSIONS: Survival for this small group of @entity1 was similar to or better than historical controls or @entity1 treated with single-fraction radiosurgery alone. This data should stimulate the investigation of both fractionated radiosurgery and the development of radiation sensitizers to further enhance treatment.

Fractionated stereotactic radiosurgery and concurrent XXXX in recurrent @entity463 multiforme: a preliminary report.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological deterioration'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['Taxol'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']
@entity1311 :: (MESH:D017239,Chemical) :: ['taxol']
